VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Significant Growth in Short Interest

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 82,600 shares, a growth of 65.2% from the October 15th total of 50,000 shares. Based on an average trading volume of 70,400 shares, the short-interest ratio is currently 1.2 days. Currently, 0.7% of the shares of the company are sold short.

Institutional Trading of VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP acquired a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics makes up about 0.0% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th biggest position. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics at the end of the most recent reporting period. 83.78% of the stock is owned by institutional investors.

VYNE Therapeutics Trading Down 2.4 %

VYNE traded down $0.07 on Thursday, reaching $2.84. The company had a trading volume of 25,666 shares, compared to its average volume of 82,782. VYNE Therapeutics has a one year low of $1.57 and a one year high of $4.48. The company has a fifty day moving average of $2.24 and a 200-day moving average of $2.18. The company has a market capitalization of $41.89 million, a P/E ratio of -3.38 and a beta of 1.32.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). VYNE Therapeutics had a negative net margin of 6,896.55% and a negative return on equity of 43.73%. The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.11 million. Research analysts predict that VYNE Therapeutics will post -0.86 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $5.75 price target on shares of VYNE Therapeutics in a research report on Friday, November 8th.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.